News
GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...
UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...
With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...
16h
Zacks Investment Research on MSNGSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook RaiseGSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...
Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...
GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...
On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...
GSK reported 4% year-on-year earnings growth (at constant currency) and core operating profit margin of 33.7%, or 30 basis points better than the same period last year. This was driven by strong ...
In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also ...
12d
Pharmaceutical Technology on MSNGSK’s Blenrep faces setback as FDA cancer committee votes against approvalThe FDA’s Oncologic Drugs Advisory Committee has voted against the benefit/risk profile of GSK’s Blenrep just days before the drug’s PDUFA date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results